One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Generate Biomedicines, Inc.
GENB · NMS · Healthcare · Biotechnology
Current price
$15.72
52-week range
$11.00 - $22.67
Market cap
$2.02B
Balance sheet
Healthy
-206.92x Concerning
Net cash $394.79M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
0 Risks
1 rewards · 0 risks
View details ↓What this company does
Generate Biomedicines, Inc.
Generate Biomedicines is a biotechnology company using artificial intelligence to design new protein-based drugs for difficult conditions like severe asthma. Because its potential medicines are still being tested and are not yet for sale, the company doesn't have revenue (money from selling products) and relies on investors to pay for its research. This is important because if its AI technology works, it could discover new treatments much faster than traditional methods.
How the company got here
Generate Biomedicines was started in 2018 by the life sciences investment firm Flagship Pioneering to build a new kind of drug company. [16] Instead of the traditional, often slow process of discovering medicines, their idea was to use artificial intelligence to design them from the ground up. After operating privately for several years and raising hundreds of millions of dollars from investors, the company became publicly traded through an IPO (Initial Public Offering, the first time a company sells its stock to the public) in early 2026 to fund its research. [3, 4]
What it actually does
Generate Biomedicines uses powerful computers and a technology called generative AI to create designs for new protein-based medicines. Proteins are the tiny machines that perform most jobs inside our cells, and many modern drugs are based on them. [32] The company's 'Generate Platform' learns the rules of how proteins work and then generates designs for entirely new ones intended to fight specific diseases like cancer or asthma. [9, 24] This approach aims to make the process of creating new drugs much faster and more predictable than the classic trial-and-error methods used by many other pharmaceutical companies. [3]
Internal Drug Development
This is the part of the company focused on creating its own medicines from start to finish. Generate uses its AI platform to design potential drugs and then moves them through development, including clinical trials (the process of testing new drugs in people to see if they are safe and effective). [29] Its most advanced potential medicine is for severe asthma and is in the final phase of testing before it can be considered for sale. [4, 10] This business does not yet generate any sales revenue (money from selling products) because all of its potential drugs are still being tested. [18]
Platform Collaborations
Generate also makes money by partnering with large, established pharmaceutical companies like Amgen and Novartis. [4, 6] In these deals, the partner pays Generate to use its AI platform to design new medicines for specific diseases they want to target. [15, 19] This provides Generate with upfront cash and the chance to earn future milestone payments (money paid when a drug successfully completes a certain stage of development) and royalties (a small percentage of sales if the drug is eventually approved and sold). [6, 12] These partnerships are a significant source of the company's current revenue and help validate its technology while its own drugs are still in development. [30]
What management is betting on now
The company's biggest bet is that its AI-powered platform can successfully and repeatedly invent new, effective medicines faster than older methods. [14] A top priority is getting its lead drug candidate (a potential medicine being tested) for severe asthma through the final, most expensive stage of clinical trials and approved for sale by regulators. [4, 10] Management is also focused on advancing its other potential medicines for cancer and other diseases into human testing. [8] They continue to form strategic partnerships with other drug companies, which provides cash and confidence in their unique approach to creating medicines. [6, 18]
Price history
How the share price has moved
—
Loading price history…
Is it cheap or expensive?
Fair value — vs current price $15.72
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $394.8M - more cash than debt. Interest coverage -206.9x.
Net debt
$-394.79M
Interest coverage
-206.92x
Generate Biomedicines, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 5 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
GENB
BASELINE
Generate Biomedicines, Inc.
Total debt $62.63M Interest coverage -206.92x This is the baseline the peer rows are being compared against.
Total debt $66.64M Interest coverage -358.08x Neither company has much profit cushion over interest right now.
Total debt $108.00M Interest coverage -157.90x Neither company has much profit cushion over interest right now.
Total debt $3.83M Interest coverage -600.09x Neither company has much profit cushion over interest right now.
Total debt $30.66M Interest coverage -11.20x Neither company has much profit cushion over interest right now.
Total debt $135.62M Interest coverage -50.24x Neither company has much profit cushion over interest right now.
What you should know
The case for and against GENB
1 Reward
0 Risks
Rewards
-
Revenue grew 55.9% last year.
Risks
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-6.89x
P/B
4.42x
P/S
76.19x
EV/EBITDA
-6.50x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
-1,134.2%
Net margin
0.0%
ROE
—
ROA
—
Health
Liquidity and balance-sheet strength
Debt / equity
0.14x
Current ratio
8.30x
Quick ratio
8.08x
Total debt
$62.63M
Total cash
$457.42M
Growth
How the business has been compounding
Revenue TTM
$26.48M
Revenue 5Y CAGR
55.9%
EPS TTM
-2.14
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-200.62M
Free CF TTM
$-204.13M
FCF margin
-770.8%
Dividend
Shareholder payout
Yield
—
Payout ratio
0.0%
Last ex-div date
—